

0480

AA

12300

~~0300~~

**TRANSMITTAL LETTER**  
(General - Patent Pending)

Docket No.  
021286/027 8719

In Re Application Of: Takahashi, et al.

SEP 24 2001

Serial No.  
09/811,367

Filing Date  
March 16, 2001

Examiner  
NYA

Group Art Unit  
1645

Title: **SOLUBLE MAST CELL FUNCTION ASSOCIATED ANTIGEN (MAFA) PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING AND USING THEM**


TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Transmitted herewith is:

- 1) Response to Notice to Comply;
- 2) Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence;
- 3) Sequence Listing (hard copy and diskette);
- 4) Statement Under 37 C.F.R. 1.821 (f) and (g); and
- 5) Reply postcard.

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☐ The Commissioner is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

  
Signature

Dated: September 21, 2001

**Robert M. Bedgood**  
Reg. N . 43,488

I certify that this document and fee is being deposited  
September 21, 2001 with the U.S. Postal Service as  
first class mail under 37 C.F.R. 1.8 and is addressed to the  
Commissioner of Patents and Trademarks, Washington,  
D.C. 20231.

  
Signature of Person Mailing Correspondence

**Linda Anders**

Typed or Printed Name of Person Mailing Correspondence

cc: SF D cketing

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Takahashi, et al.

Serial No.: 09/811,367

Filed: March 16, 2001



Examiner: NYA

Group Art Unit: 1645

Docket: 021286/027 8719

For: **SOLUBLE MAST CELL FUNCTION ASSOCIATED ANTIGEN (MAFA)  
PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING AND  
USING THEM**

---

RESPONSE TO NOTICE TO COMPLY

Commissioner of Patents  
Washington, D.C. 20231

Sir:


Responsive to the communication mailed August 21, 2001, Applicants submit herewith a paper copy and a computer readable form (diskette) of the sequence listing as required under 37 C.F.R. §1.824 (a). The sequence listing is provided in ASCII text on the accompanying diskette. A copy of the notice to comply is attached to this response.

The paper copy and computer readable forms of the sequence listing are identical and do not add new matter. A statement under 37 C.F.R. §1.821 (f) and (g) to that effect is provided. Accordingly, please amend the specification by entering the enclosed sequence listing.

Respectfully submitted,

PILLSBURY WINTHROP LLP

Date: 9-21-01

  
Robert M. Bedgood  
Reg. No. 43,488



UNITED STATES PATENT AND TRADEMARK OFFICE



COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/811,367	03/16/2001	Nobuaki Takahashi	021286/027 8719

**CONFIRMATION NO. 6403**

**FORMALITIES LETTER**



\*OC000000006453365\*

Robert M. Bedgood  
5th Floor  
50 Fremont Street  
San Francisco, CA 94105-2230

Date Mailed: 08/21/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

*Ngan*  
\_\_\_\_\_  
Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE